Trial Outcomes & Findings for Digital Therapeutic for Chronic Pain Feasibility Study (NCT NCT06000007)

NCT ID: NCT06000007

Last Updated: 2026-03-31

Results Overview

This self-report questionnaire consists of is a six-item that assesses the impact of pain on various aspects of a person's life (e.g., social, cognitive, emotional, physical and recreational activities) over the last 7 days. Responses are scored using a 5-point ordinal rating scale from 1 to 5 (1=Not at all, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Very much). Raw score totals are converted to T-score using the scoring manual. T-score of 50 is the mean for the U.S. general population with a standard deviation of 10; the higher the T-score, the worse the pain interference.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

108 participants

Primary outcome timeframe

will be measured at baseline, 1-month, 3-month, and 6 month intervals

Results posted on

2026-03-31

Participant Flow

Eligibility: aged \>=18, pain experience current and present for \>=3 months, \>=1 ICD code for common pain related condition, \>=2 primary care visits within last 12 months at time of recruitment, PROMIS Pain Interference Short Form 6b T-score \>=55, daily smartphone access, ability to download an app, willingness to engage in a 3-month chronic pain self-management program administered via an app, speak English, and consented. Exclusions: cancer pain surgery within 3 months, pregnant, on hospice.

Patients were invited to participate via direct email with a link to an interest survey with three options: eligibility survey vs request a call back vs opt out. Those eligible were directed to an e-consent form requiring confirmation vs request a call vs confirm that they no interest in participation. Patients who confirmed interest were asked to e-consent. A study coordinator counter-signed the e-consent form and follow up with any call requests, and if needed assist with consent by phone.

Participant milestones

Participant milestones
Measure
Treatment as Usual
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
Intervention Arm
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
Overall Study
STARTED
43
49
Overall Study
COMPLETED
40
38
Overall Study
NOT COMPLETED
3
11

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Digital Therapeutic for Chronic Pain Feasibility Study

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treatment as Usual
n=43 Participants
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
Intervention Arm
n=49 Participants
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
Total
n=92 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=4 Participants
0 Participants
n=28 Participants
0 Participants
n=10 Participants
Age, Categorical
Between 18 and 65 years
34 Participants
n=4 Participants
38 Participants
n=28 Participants
72 Participants
n=10 Participants
Age, Categorical
>=65 years
9 Participants
n=4 Participants
11 Participants
n=28 Participants
20 Participants
n=10 Participants
Sex/Gender, Customized
Gender
0 Participants
n=4 Participants
0 Participants
n=28 Participants
0 Participants
n=10 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=4 Participants
0 Participants
n=28 Participants
0 Participants
n=10 Participants
Race (NIH/OMB)
Asian
4 Participants
n=4 Participants
7 Participants
n=28 Participants
11 Participants
n=10 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=4 Participants
2 Participants
n=28 Participants
2 Participants
n=10 Participants
Race (NIH/OMB)
Black or African American
6 Participants
n=4 Participants
7 Participants
n=28 Participants
13 Participants
n=10 Participants
Race (NIH/OMB)
White
22 Participants
n=4 Participants
21 Participants
n=28 Participants
43 Participants
n=10 Participants
Race (NIH/OMB)
More than one race
9 Participants
n=4 Participants
8 Participants
n=28 Participants
17 Participants
n=10 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=4 Participants
4 Participants
n=28 Participants
6 Participants
n=10 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
10 Participants
n=4 Participants
9 Participants
n=28 Participants
19 Participants
n=10 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
32 Participants
n=4 Participants
40 Participants
n=28 Participants
72 Participants
n=10 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
1 Participants
n=4 Participants
0 Participants
n=28 Participants
1 Participants
n=10 Participants

PRIMARY outcome

Timeframe: will be measured at baseline, 1-month, 3-month, and 6 month intervals

Population: The difference in sample size between the Participant Flow section and this section is due to incomplete surveys, which were excluded from the analysis.

This self-report questionnaire consists of is a six-item that assesses the impact of pain on various aspects of a person's life (e.g., social, cognitive, emotional, physical and recreational activities) over the last 7 days. Responses are scored using a 5-point ordinal rating scale from 1 to 5 (1=Not at all, 2=A little bit, 3=Somewhat, 4=Quite a bit, 5=Very much). Raw score totals are converted to T-score using the scoring manual. T-score of 50 is the mean for the U.S. general population with a standard deviation of 10; the higher the T-score, the worse the pain interference.

Outcome measures

Outcome measures
Measure
Treatment as Usual
n=38 Participants
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
Intervention Arm
n=46 Participants
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
PROMIS Pain Interference Scale - Short Form 6b
baseline difference scores
62.1 T-score - difference scores between arms
Standard Deviation 5.5
62.1 T-score - difference scores between arms
Standard Deviation 4.2
PROMIS Pain Interference Scale - Short Form 6b
1-month different scores
62.8 T-score - difference scores between arms
Standard Deviation 5.7
60.8 T-score - difference scores between arms
Standard Deviation 5.6
PROMIS Pain Interference Scale - Short Form 6b
3-month difference
61.9 T-score - difference scores between arms
Standard Deviation 6.2
61.2 T-score - difference scores between arms
Standard Deviation 5.6
PROMIS Pain Interference Scale - Short Form 6b
6-month difference
61.0 T-score - difference scores between arms
Standard Deviation 6.1
59.9 T-score - difference scores between arms
Standard Deviation 5.7

SECONDARY outcome

Timeframe: will be measured at baseline, 1-month, 3-month, and 6 month intervals

Population: The difference in sample size between the Participant Flow section and this section is due to incomplete surveys, which were excluded from the analysis.

This self-report questionnaire consists of 9 items assessing depressive symptoms consistent with criteria for Major Depressive Disorder over the past two weeks. Each item is rated on a 4-point Likert scale (0 = not at all, 1 = several days, 2 = more than half the days, 3 = nearly every day). Item scores are summed to produce a total score ranging from 0 to 27, with higher scores indicating greater severity of depressive symptoms (worse outcome). A typical cut-off score for probable depression is ≥ 10 points. The measure has demonstrated strong psychometric properties, including high levels of sensitivity and specificity for identifying major depressive disorder.

Outcome measures

Outcome measures
Measure
Treatment as Usual
n=40 Participants
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
Intervention Arm
n=49 Participants
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
Patient Health Questionnaire 9 (PHQ-9)
baseline difference
8.2 units on a scale
Standard Deviation 6.1
8.5 units on a scale
Standard Deviation 5.1
Patient Health Questionnaire 9 (PHQ-9)
1-month difference
8.3 units on a scale
Standard Deviation 6.4
8.7 units on a scale
Standard Deviation 5.3
Patient Health Questionnaire 9 (PHQ-9)
3-month difference
8.8 units on a scale
Standard Deviation 5.8
7.9 units on a scale
Standard Deviation 5.9
Patient Health Questionnaire 9 (PHQ-9)
6-month difference
7.7 units on a scale
Standard Deviation 5.7
8.6 units on a scale
Standard Deviation 5.4

SECONDARY outcome

Timeframe: will be measured at baseline, 1-month, 3-month, and 6 month intervals

Population: The GAD-7 measure was accidentally left off of the baseline measure for some participants at the start of the study, so the total # of GAD-7 baseline participants is lower than the total # for the other outcome measures.

anxiety symptom measure; scores range from 0-21; higher scores are worse

Outcome measures

Outcome measures
Measure
Treatment as Usual
n=38 Participants
Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.
Intervention Arm
n=48 Participants
Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual
Generalized Anxiety Disorder 7 (GAD-7)
baseline difference
6.6 units on a scale
Standard Deviation 5.6
8.2 units on a scale
Standard Deviation 5.3
Generalized Anxiety Disorder 7 (GAD-7)
1-month difference
6.9 units on a scale
Standard Deviation 6.1
8.0 units on a scale
Standard Deviation 5.5
Generalized Anxiety Disorder 7 (GAD-7)
3-month difference
6.8 units on a scale
Standard Deviation 5.2
7.2 units on a scale
Standard Deviation 5.9
Generalized Anxiety Disorder 7 (GAD-7)
6-month difference
6.3 units on a scale
Standard Deviation 57
7.0 units on a scale
Standard Deviation 5.4

Adverse Events

Treatment as Usual

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Intervention Arm

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Kari A. Stephens

University of Washington

Phone: 206-221-0349

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place